Antifungal activity of Limosilactobacillus reuteri against Candida albicans and non-Candida albicans Candida

Authors

  • António Rajão Associate Laboratory i4HB – Institute for Health and Bioeconomy, University Institute of Health Sciences – CESPU, 4585-116 Gandra, Portugal; UCIBIO – Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal
  • Paulo Rompante UNIPRO – Oral Pathology and Rehabilitation Research Unit, CESPU, CRL, 4585-116 Gandra, Portugal
  • Célia F. Rodrigues Associate Laboratory i4HB – Institute for Health and Bioeconomy, University Institute of Health Sciences – CESPU, 4585-116 Gandra, Portugal; UCIBIO – Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal
  • José Carlos Andrade Associate Laboratory i4HB – Institute for Health and Bioeconomy, University Institute of Health Sciences – CESPU, 4585-116 Gandra, Portugal; UCIBIO – Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal https://orcid.org/0000-0002-2403-6062

DOI:

https://doi.org/10.48797/sl.2024.168

Keywords:

Poster

Abstract

Background: Oral candidiasis is one of the most present fungal infections, with Candida albicans being the foremost responsible for this infection, but in recent years the non-Candida albicans Candida species play a significant role in the rise of cases of oral candidiasis [1]. Phenomena of resistance to regular antifungals are rising, which makes it harder to control cases of oral candidiasis. Thus, searching for new approaches like probiotics, and their use in the oral cavity, becomes necessary and urgent [2]. Here we present the antifungal activity of newly isolated oral strain of Limosilactobacillus reuteri, a potential probiotic. Objective: Evaluation of Limosilactobacillus reuteri AJCR antifungal activity against reference strains of Candida spp.. Methods: Limosilactobacillus reuteri AJCR was isolated from the oral cavity of a healthy, caries free, volunteer, following the methodology of Rossini et al. [2]. Four reference strains, Candida albicans SC14, Nakaseomyces glabrata ATCC2001, C. tropicalis ATCC750, and C. parapsilosis ATCC22019, were used to evaluate the antifungal activity in planktonic cells. The methodology followed was adapted from the EUCAST guidelines. Different amounts of L. reuteri (108-102 CFU/mL, final concentration) were added, to standardized suspensions of the Candida strains studied. Results: At L. reuteri concentration of 108 CFU/mL, no viable cells of C. albicans SC5314 and of C. tropicalis ATCC750 were detected. At the same concentration, Nakaseomyces glabrata ATCC2001 suffered a reduction in growth of around 4 Log. Candida parapsilosis ATCC22019 suffered a reduction of around 2 Log at concentration of 107 CFU/mL of the oral isolate. Conclusions: Limosilactobacillus reuteri AJCR has shown an excellent antifungal activity against planktonic cells of C. albicans SC5314 and C. tropicalis ATCC750, and a significant reduction in the growth of Nakaseomyces glabrata ATCC2001 and C. parapsilosis ATCC22019. To further characterize the antifungal activity of the isolate, studies with biofilm cultures must be performed.

References

1. Černáková, L.; Rodrigues, C.F. Microbial interactions and immunity response in oral Candida species. Future Microbiol 2020, 15(17), 1653-1677.

2. Rossoni, R.D.; de Barros, P.P.; de Alvarenga, J.A.; Ribeiro. F.C.; Velloso, M.S.; Fuchs, B.B.; Mylonakis, E.; Cardoso Jorge, A.O.; Campos Junqueira, J. Antifungal activity of clinical Lactobacillus strains against Candida albicans biofilms: identification of potential probiotic candidates to prevent oral candidiasis. Biofouling 2018, 34(2), 212-225.

3. European Committee on Antimicrobial Susceptibility Testing. Overview of antifungal ECOFFs and clinical breakpoints for yeast, moulds and dermatophytes using the EUCAST E.Def 7.4, E.Def 9.4 and E.Def 11.0 procedures. 2023. Available online: https://www.eucast.org/astoffungi/clinicalbreakpointsforantifungals (accessed on 9 October 2023).

Downloads

Published

2024-05-01

How to Cite

Rajão, A., Rompante, P., F. Rodrigues, C., & Andrade, J. C. (2024). Antifungal activity of Limosilactobacillus reuteri against Candida albicans and non-Candida albicans Candida. Scientific Letters, 1(Sup 1). https://doi.org/10.48797/sl.2024.168

Issue

Section

Posters

Most read articles by the same author(s)

Similar Articles

<< < 6 7 8 9 10 11 12 13 14 15 > >> 

You may also start an advanced similarity search for this article.